Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 73

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 73
---
 major commercial markets;

    ●
    we
    may not develop additional proprietary technologies that are patentable;

    ●
    we
    cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications
    that we own or in-license will result in issued patents with claims that are directed to our diagnostic tests and product candidates
    or uses thereof in the U.S. or foreign countries;

    ●
    there
    may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection
    both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health
    concerns;

    ●
    countries
    other than the U.S. may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors
    a better opportunity to create, develop, and market competing diagnostic tests and product candidates;

    ●
    the
    claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages,
    or may be challenged by third parties; and

    ●
    if
    enforced, a court may not hold that our patents are valid, enforceable, and infringed.

If
we fail to comply with our obligations imposed by any intellectual property licenses with third parties that we may need in the future,
we could lose rights that are important to our business.

We may in the future require licenses to third-party technology and materials. Such licenses may not be available
in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business
and financial condition. We may in the future rely on third parties from whom we license proprietary technology to file and prosecute
patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control
over these activities or any other intellectual property that may be related to future in-licensed intellectual property. For example,
we cannot be certain that such activities by these licensors will be conducted in compliance with applicable laws and regulations or will
result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our
licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights or defend certain of
the intellectual property that may be licensed to us. It is possible that the licensors’ infringement proceeding or